Moderna’s Bid For Second COVID Vaccine Booster Spans Broader Age Group Than Pfizer/BioNTech

US FDA advisory committee will meet in April to discuss whether and when boosters may be needed and for whom; Moderna seeks authorization for second booster dose in everyone ≥18 years, while Pfizer/BioNTech have limited their request to individuals ≥65 years.

Paint brushes
Moderna is using broad brush strokes in its bid for authorization of a second booster dose, compared to Pfizer/BioNTech's narrower request. • Source: Alamy

Moderna, Inc.’s request for US emergency use authorization of a second COVID-19 vaccine booster shot in the general adult population marks the company’s first bid to move past rivals Pfizer Inc./BioNTech SE in breadth of indication for the competing mRNA products.

On 17 March, Moderna announced it had submitted a request to the Food and Drug Administration for an additional booster...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet